Healthcare >> CEO Interviews >> December 2, 1999
SCOTT M. ROCKLAGE currently serves as Chairman and CEO of Cubist
Pharmaceuticals, Inc. Dr. Rocklage was elected Chairman of the Board of
Directors in March 2000. He has served as Chief Executive Officer and as
a member of the Board of Directors of Cubist Pharmaceuticals since July
1994. Dr. Rocklage also served as Cubist's President from July 1994
until March 2001. From 1990 to 1994, Dr. Rocklage served as President
and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic
imaging company and from 1992 to 1994, he also served as Chairman,
President and Chief Executive Officer of Nycomed Interventional, Inc., a
medical device company. From 1986 to 1990, he served in various
positions at Nycomed Salutar, Inc., and was responsible for designing
and implementing research and development programs that resulted in
three drug products in human clinical trials, including the approved
drugs Omniscan and Teslascan. Dr. Rocklage has also served as a director
of MDS Proteomics, Inc., since July 2001. He received his BS in
Chemistry from the University of California, Berkeley, and his PhD in
Chemistry from the Massachusetts Institute of Technology. Profile
Dr. Rocklage: Cubist's mission is based on the discovery of novel
antiinfectives to treat serious and life-threatening
